A study indicates an essential link between a mild deterioration in excretory kidney function and the risk of neutropenia during cancer chemotherapy.

ABSTRACT:

Purpose

Neutropenia, defined as a number of neutrophils in patients' blood specimen lower than 1500 cells/μm³, is a common adverse event during myelosuppressive oncological chemotherapy, predisposing to febrile neutropenia (FN). Patients with coexisting moderate-to-severe chronic kidney disease (CKD) have an increased risk of FN, included in the guidelines for the primary prophylaxis of FN. However, this does not include mild kidney function impairment with estimated glomerular filtration rate (eGFR) 60-89 ml/min/1.73 m². This prospective study analyzed the risk of neutropenia in patients on chemotherapy without indication for the primary prophylaxis of FN.

Methods

The study enrolled 38 patients starting chemotherapy, including 26 (68.4%) patients aged

SUBMITTER: Stryczynska-Mirocha A 

PROVIDER: S-EPMC10473980 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature